Helene Devold

Post Doc, Ph.D., MScPharm


Norwegian Institute of Public Health, Department of chronic diseases

Areas of interest:

Pharmacoepidemiology, osteoporosis



Basic profession


Academic degrees

MSc, University of Oslo, 2007
PhD, University of Oslo, 2012

Professional experience

Advisor at Norwegian Institute of Public Health, Department of Pharmacoepidemiology, and WHO Collaborating Centre for Drug Statistics Methodology

Dissemination 2007-2010

Oral presentations in 2 scientific meetings and poster presentations at 5 scientific meetings.



• Devold HM, Søgaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 2013 Apr;24(4):1225-33.

• Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21(8):881-5.

• Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Søgaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf 2012; 21: 297-304.

• Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Søgaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol. 2010 Mar;66(3):299-306.

• Devold HM, Molden E, Skurtveit S, Furu K. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. British Journal of Clinical Pharmacology. 67(2):234-41, 2009 Feb.

← Back to researchers

Norwegian Epidemiologic Osteoporosis Studies | E-mail: norepos@fhi.no